Indivior PLC is a global healthcare company focused primarily on the treatment of addiction and serious mental health conditions. It specializes in developing and commercializing innovative pharmaceutical products designed to support individuals struggling with substance use disorders, particularly opioid addiction. The company's portfolio includes medications that facilitate recovery by reducing cravings and withdrawal symptoms, thereby helping patients manage their addiction effectively. Indivior is committed to advancing research and development in this field, aiming to improve patient outcomes and support the global effort to combat addiction through comprehensive treatment solutions. Read More
A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors.
Divisadero’s $95 million selloff sends a message about where Remitly stands in the shifting economics of global money movement. Here’s what that signal may mean for long-term investors.
With a strong position in a niche yet vital therapeutic area, Indivior PLC benefits from durable brand equity, a specialized distribution network, and a long runway for product innovation.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade.
